SEC EDGAR · Jul 31, 11:03 AM UTC
8-K — Moderna, Inc
Historical operation · Retained
“Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)”
Quoted source · 14 source segments
- [1] exhibit9912026q2pressrelea.htm
- [2] exhibit9912026q2pressrelea.htm
- [3] exhibit9912026q2pressrelea.htm
- [4] exhibit9912026q2pressrelea.htm
- [5] exhibit9912026q2pressrelea.htm
- [6] exhibit9912026q2pressrelea.htm
- [7] exhibit9912026q2pressrelea.htm
- [8] exhibit9912026q2pressrelea.htm
- [9] exhibit9912026q2pressrelea.htm
- [10] exhibit9912026q2pressrelea.htm
- [11] exhibit9912026q2pressrelea.htm
- [12] exhibit9912026q2pressrelea.htm
- [13] exhibit9912026q2pressrelea.htm
- [14] exhibit9912026q2pressrelea.htm
Model assessment
The 8-K and press release provide a comprehensive update on Moderna's Q2 2026 results and 2026 guidance. While the company improved its operating expense outlook and reiterated its revenue growth target, it also reported a significant net loss, a decline in cash position, and a Phase 3 trial miss for its norovirus vaccine candidate. The evidence presents a mixed picture with both positive and negative catalysts, but no single material event or fundamental change that clearly supports a BUY or SELL operation. The information is informational and does not provide a clear directional signal for the target.
14 exact filing citations